利妥昔单抗配合CHOP化疗对非霍奇金淋巴瘤患者血清TK-1、VEGF的影响

Effects of rituximab combined with CHOP chemotherapy on serum TK-1 and VEGF levels in patients with non-Hodgkin′s lymphoma

目的研究利妥昔单抗配合CHOP化疗对非霍奇金淋巴瘤患者血清胸苷激酶1(TK-1)、血管内皮生长因子(VEGF)的影响,为临床研究提供指导。方法将2013年1月至2016年3月期间于该院进行治疗的24例非霍奇金淋巴瘤患者按随机数字表法分为对照组和观察组,各12例。所有患者治疗前后均进行常规检查,对照组患者仅采用CHOP化疗,观察组采用利妥昔单抗配合CHOP化疗进行治疗。治疗后1~2年对患者进行随访,观察患者治疗效果,测量患者TK-1和VEGF水平,记录患者不良反应发生率。结果观察组和对照组患者治疗后的有效率分别为66.67%和50.00%,观察组疗效明显优于对照组,两组比较差异有统计学意义(P<0.05);治疗后两组患者的TK-1和EEGF两项指标均显著下降(P<0.05),较治疗前有统计学差异,但观察组两项指标明显低于对照组,差异具有显著性(P<0.05);两组患者治疗后对照组肝功能障碍1例,胃肠功能障碍4例,白细胞降低1例,观察组则分别为1、3、1例,两组比较差异无统计学意义(P>0.05)。结论采用利妥昔单抗配合CHOP化疗方式治疗非霍奇金淋巴瘤患者,患者病情恢复,血清TK-1、VEGF水平显著下降,减少了不良反应,值得在临床推广和应用。

Objective To study the effects of rituximab combined with CHOP chemotherapy on serum Thymidine kinase 1（TK-1）and vascular endothelial growth factor（VEGF）in patients with non-Hodgkin lymphoma,and to provide guidance for clinical research.Methods A total of 24 patients with non-Hodgkin′s lymphoma treated in our hospital from January 2013 to March 2016 were randomly divided into the control group and the observation group,and each with 12 cases.All patients were examined before and after treatment,the control group was only treated with CHOP chemotherapy,and the observation group was treated with rituximab combined with CHOP chemotherapy.The patients were followed up within 1-2 years after treatment.The therapeutic effects of all patients were observed,the TK-1 and VEGF levels were measured and the incidence rate of adverse reactions was recorded.Results The efficiency rates of patients in the observation group and the control group were 66.67% and 50.00%,respectively after treatment,and the observation group was significantly better than the control group,the difference was statistically significant（P〈0.05）;the TK-1 and VEGF levels of the two groups were significantly decreased after treatment（P〈0.05）,there was a statistically significant difference.But the two indexes of observation group was significantly lower than the control group,the difference was significant（P〈0.05）;the control group showed 1 case of liver dysfunction after treatment,4 cases of gastrointestinal dysfunction,1 case of decreased white blood cells,while the observation group were 1,3 and 1 case,respectively.There were no significant differences between two groups（P〉0.05）.Conclusion With the treatment of rituximab combined with CHOP chemotherapy,serum TK-1 and VEGF levels of patients with non-Hodgkin lymphoma decreased significantly,the poor prognosis has been significantly improved,and this treatment is worth popularizing in clinical application.